



Editorial

Annual Report 2025

Marcella Reale¹ and Xu Guo^{2,*}

¹ Department of Innovative Technologies in Medicine and Dentistry, Unit of Immunity and Molecular Pathology, School of Medicine and Health Sciences, University “G. d’Annunzio” Chieti-Pescara, Via dei Vestini, 66100 Chieti, Italy

² AIMS Press, Springfield, MO 65801-2604, USA

* **Correspondence:** Email: allergy.immunol@aimspress.org.

Abstract: This editorial note presents the 2025 annual report of *AIMS Allergy and Immunology* published by AIMS Press. Following a concise overview of the journal’s development in 2025, we propose prospective directions for its advancement in 2026.

1. Journal summary from Editor in Chief

AIMS Allergy and Immunology is an international Open Access journal devoted to publishing peer-reviewed, high quality, original papers in the field of immunology and allergy. At the beginning of the new year and together with the Editorial Office of *AIMS Allergy and Immunology*, I wish to testify my sincere gratitude to all authors, members of the editorial board and reviewers for their contribution to *AIMS Allergy and Immunology* in 2025. We have achieved substantial progress in 2025 and anticipate an even more productive year in 2026.

In 2025, We received 35 manuscripts and 20 were published; these published papers include 7 Review articles, 6 Research articles, 4 Case report, 2 Editorial, and 1 Protocol. The contributing authors are affiliated with institutions from 14 countries. The data shows a significant increase of international collaborations on the research of allergy and immunology. It now is a significant presence in the academic publishing market. During this 2025 we had 43% rejection ratio and publication time (from submission to online) was 111 days, illustrating the strict and efficient review process.

In recognition of authors’ expertise the Best Paper Award was launched by *AIMS Allergy and Immunology* and the manuscript “MicroRNA-155 is a critical regulator of regulatory T cells in

OM-85 Broncho-Vaxom treated experimental models of allergic rhinitis.” (*AIMS Allergy and Immunology*, 2024, 8(1): 8–17) was the winner.

AIMS Allergy and Immunology editorial board has 74 members now. We will continue to renew and accept dedicated researchers to join the Editorial Board in 2026. One of the important strategies of attracting high quality and high impact papers to our journal has been the calls for special issues. In 2025, one special issues were established.

The road ahead remains long and challenging, but we hope that in 2026, with the support of all the members of the editorial board and reviewers, *AIMS Allergy and Immunology* can receive and collect more excellent articles to be able to publish. The journal will dedicate to publishing high quality papers by regular issues as well as special issues organized by the members of the editorial board. We believe that all these efforts will increase the impact and citations of the papers published by *AIMS Allergy and Immunology*.

Please feel free to let us know your opinions, we will follow your suggestions and make updates to improve *AIMS Allergy and Immunology*.

Prof. Marcella Reale, Editor-in-Chief
AIMS Allergy and Immunology journal
Dept. of Innovative Technologies in Medicine and Dentistry
University “G. d’Annunzio” Chieti-Pescara; Via dei Vestini, Chieti, Italy

2. Editorial development

2.1. Manuscripts statistics

In 2025, *AIMS Allergy and Immunology* journal published 4 issues, a total of 20 articles were published online. The category of published articles is shown in Table 1. These published papers include 7 Review articles, 6 Research articles, 4 Case report, 2 Editorial and 1 Protocol. The journal received a total of 35 submissions (Figure 1). Both the number of submissions and the number of publications remained stable. The publication time (from submission to online) was 111 days, illustrating the efficient review process. In 2025, *AIMS Allergy and Immunology* places greater emphasis on publishing high-quality articles and hopes to receive more citations.

Table 1. The category of published articles.

Type	Number
Review	7
Research article	6
Case report	4
Editorial	2
Protocol	1



Figure 1. Number of submissions and publications in the past 3 years.

2.2. Author distribution

Figures 2 and 3 provide the counts of submitted and online manuscripts per country. The countries are derived by affiliation of the corresponding author. In 2025, we received 35 submissions from 14 countries, which shows the diversity of the author distribution. We would like to express our gratitude to all authors for their trust and support of *AIMS Allergy and Immunology*. We firmly believe that this widely distributed and powerful group has promoted the development of materials science.




Figure 2. Submitted articles by country and region.




Figure 3. Online articles by country and region.

2.3. Articles metrics

Table 2 shows the top ten manuscripts in terms of downloads and views in last two years. This will be a motivation for the future promotion of journals and to help them get into the desired databases as early as possible (Data from journal homepage as of March 06, 2026).

Table 2. The top 10 articles with highest viewed in last 2 years.

No.	Title	Viewed
1	Dietary and orally-delivered miRNAs: Are they functional and ready to modulate immunity?	7054
2	Non-allergic rhinitis with eosinophilia syndrome treated with mepolizumab: A case report	6524
3	Angioedema-post COVID symptoms	6209
4	Role of IgG food test in patients with allergic diseases	5928
5	A systematic review of the knowledge and training of food service workers on food allergies	5382
6	Rare dizziness, syncope, loss of consciousness, seizure, and risk of falling after vaccination	5303
7	Epigenetic regulation of the COVID-19 pathogenesis: its impact on the host immune response and disease progression	5086
8	Mast cells in severe respiratory virus infections: Insights for treatment and vaccine administration	5086
9	Scoping review on severe asthma: Cytokines, cells, triggers and multi-omics approaches	5080
10	Exploring ginseng's potential role as an adjuvant therapy in COVID-19	4994

Table 3 shows the top ten manuscripts in terms of citations in last three years. This will help us increase the visibility and impact of the journal (Data from Web of Science as of March 06, 2026).

Table 3. The top 10 articles with highest citations in last 3 years.

No.	Article	Citations
1	Antibody profiling reveals gender differences in response to SARS-COVID-2 infection	5
2	Understanding sex differences in the allergic immune response to food	5
3	Dietary and orally-delivered miRNAs: are they functional and ready to modulate immunity?	4
4	Multiple sclerosis and allergic diseases: is there a relationship?	3
5	Contrast allergies for neurological imaging: When to proceed	3
6	Migratory dermatographic urticaria following COVID-19 vaccine booster in young adult male	3
7	Impact of etiological factors on citrullination markers and susceptibility of PADI4 allele for CHIKV induced rheumatoid arthritis among South Indian Tamil RA cases	3
8	The immune system through the ages	3
9	The gastrointestinal effects amongst Ehlers-Danlos syndrome, mast cell activation syndrome and postural orthostatic tachycardia syndrome	3
10	Angioedema-post COVID symptoms	2

2.4. Special issue in 2025

In 2025, *AIMS Allergy and Immunology* has launched one new special issue. In addition, one special issue has published more than 5 articles. We hope that these special issues will attract more high-quality submissions in 2026.

Table 4. Special issues in 2025.

No.	Special issue	Link
1	Recent Advances in the Diagnosis and Treatment of Kawasaki Disease (more than 5 papers)	https://www.aimspress.com/allergy/article/6849/special-articles
2	Immune side-effect with long-term and short-term observation from vaccine (new)	https://www.aimspress.com/allergy/article/7114/special-articles

2.5. Editorial board members

AIMS Allergy and Immunology has Editorial Board members representing researchers from 20 countries, representing a diverse range of research experience, expertise and countries. We are constantly assembling the editorial board to be representative to a variety of disciplines across the field of allergy and immunology. *AIMS Allergy and Immunology* has 74 members now (Figure 4). Our EB members are mainly from the United States, Italy, Korea, Australia and Canada. We will continue to invite dedicated experts and researchers in order to renew the Editorial Board in 2026.




Figure 4. Country distribution of editorial board members.

2.6. Summary & plan

2.6.1. Summary

In 2025, *AIMS Allergy and Immunology* maintained steady and healthy development. We have received 35 submissions and published 20 papers. The journal continued to attract high-quality submissions from authors worldwide.

The peer-review process remained rigorous and efficient. The manuscript processing period and acceptance rate stayed stable. Every submitted article was handled carefully, fairly, and promptly, ensuring that accepted papers were published in a timely manner.

With the strong support of guest editors, the journal successfully launched one new special issue, and one special issue published more than five high-quality articles.

With the joint efforts of the editorial board, editor-in-chief, authors, and reviewers, the journal's academic influence continued to grow. *AIMS Allergy and Immunology* will further improve its publishing standards and strive to provide a better academic platform for global researchers in the fields of allergy and immunology.

2.6.2. Plan in 2026

In 2026, *AIMS Allergy and Immunology* will continue to focus on improving academic quality and international influence. Our core objective is to attract outstanding authors and high-quality papers in allergy and immunology, steadily increase citations, and provide a reliable academic platform for the global scientific community.

To achieve these goals, the key work plans for 2026 are as follows: (1) Invite more renowned experts and active scholars in allergy and immunology to publish high-level reviews and original research articles, enhancing the journal's academic depth and diversity. (2) Strengthen the planning, solicitation and promotion of special issues, focusing on frontier research directions to boost the journal's visibility and attractiveness. (3) Accelerate the application for inclusion in more authoritative academic databases to expand international exposure and citation opportunities. (4) Optimize and expand the Editorial Board by introducing outstanding scholars with international backgrounds, improving the rigor and efficiency of peer review. (5) Continue the Best Paper Award to encourage high-quality submissions and recognize excellent academic achievements. (6) Shorten the manuscript processing cycle, ensure fair and efficient review, and accelerate the publication of accepted papers to enhance author experience.

Due to the decline in the journal's Impact Factor (IF) in 2024, we encourage members of the Editorial Board to actively promote the journal within their academic networks and look forward to editors taking the initiative in planning new special issues or thematic sections, continuously improving the quality of submissions through targeted invitations. We will regularly monitor the journal's performance metrics, flexibly adjust strategies based on data analysis, and jointly drive the long-term development of the journal.

We will strive to promote the long-term and stable development of the journal through the above measures.

Acknowledgments

We sincerely appreciate the time, dedication and invaluable expertise contributed by all our editorial board members, guest editors and reviewers. Throughout 2025, these distinguished experts have provided us with highly professional, constructive and insightful comments and suggestions. We extend our deepest gratitude to each and every one of you.

Last but not least, we wish to express our sincere thanks to the diligent in-house editorial team for their relentless efforts and outstanding support throughout the year.



© 2026 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>)